TwinBeech Capital’s ChemoCentryx, Inc. CCXI Stock Holding History

TwinBeech Capital’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10,663	Closed	-$264K	–	869
2022 Q2	$264K	Buy	+10,663	New	+$235K	0.01%	460
2021 Q1	–	Sell	-3,395	Closed	-$210K	–	716
2020 Q4	$210K	Buy	+3,395	New	+$194K	0.03%	405
2020 Q2	–	Sell	-11,118	Closed	-$447K	–	520
2020 Q1	$447K	Buy	+11,118	New	+$472K	0.18%	164

Other funds holding CCXI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

TwinBeech Capital's CCXI Position: Q3 2022 in Review

TwinBeech Capital sold out of ChemoCentryx, Inc. (CCXI) in Q3 2022, closing a stake of 10,663 shares — an estimated $264K sold.

TwinBeech Capital first reported a position in CCXI in Q1 2020 and held it in 3 quarters. The position peaked at $447K in Q1 2020. 217 funds tracked by Wall St. Rank hold CCXI as of Q3 2022.

TwinBeech Capital reported no remaining ChemoCentryx, Inc. position as of Q3 2022 after selling out during the quarter.
TwinBeech Capital sold 10,663 ChemoCentryx, Inc. shares in Q3 2022, an estimated $264K.
TwinBeech Capital first reported a position in ChemoCentryx, Inc. in Q1 2020 and held it in 3 quarters.
TwinBeech Capital's ChemoCentryx, Inc. position peaked at $447K in Q1 2020.
217 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q3 2022.

Based on TwinBeech Capital's 13F filing for Q3 2022, filed 14 Nov 2022.